<DOC>
	<DOCNO>NCT01174953</DOCNO>
	<brief_summary>The purpose study study molecular effect chemopreventative agent , finasteride , combination dietary soy supplementation patient high risk development prostate cancer . Also , investigator intend create large database health information men high risk develop prostate cancer , along serum tissue sample patient willing provide tissue serum sample .</brief_summary>
	<brief_title>High Risk Prostate Cancer Prevention Study</brief_title>
	<detailed_description>Over 180,000 new case prostate cancer diagnose United States year , make prostate cancer frequently diagnose cancer men . With estimate 28,660 death occur 2008 , prostate cancer second lead cause cancer death men . In Kansas , prostate cancer also frequent cancer among men rank third ( 253 death 2006 ) behind lung cancer ( 884 death 2006 ) colorectal cancer ( 273 death 2006 ) cancer relate mortality . Despite significant morbidity mortality related disease , screen treatment approach remain controversial significant morbidity relate treatment early stage disease . Preventative strategy strategy identify patient high risk need desperately . The goal proposal study molecular effect chemopreventative agent , finasteride combination dietary soy supplementation patient high risk development prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Based PSA , DRE Family history prostate cancer patient risk stratify use Prostate Cancer Risk Calculator . Must least 25 % chance prostate cancer development assess prostate cancer risk calculator . 2 . During time study period , patient must agree take new vitamin supplementation , soy herbal supplement . 3 . Must receive concurrent chemotherapy , radiation hormonal therapy . 4 . No history prior allergy intolerability soybased product . 5 . Must take soy supplementation , soy isoflavones finasteride within 90 day prior study enrollment . 6 . Must able safely study supplement period least four month . 7 . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . 8 . All patient must willing undergo prestudy followup assessment , include prostate biopsy . 1 . Patients diagnosed prostate cancer initial biopsy 2 . Patients active malignancy 3 . Receiving concurrent chemotherapy , hormonal therapy radiation 4 . Patient compliant treatment least 4 month 5 . Patients history deep vein thrombosis , myocardial infarction , coronary artery disease , cerebrovascular accident last 6 month also exclude . 6 . Patients active anticoagulation exclude . 7 . Patients liver function test 2 level upper limit normal 8 . Patients develop grade 2 toxicity also remove study</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>